BY SEAN WHOOLEY
MassDevice — Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round.
Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management.
Milpitas, Calif.-based Bigfoot said in a news release that the proceeds will support product development and the regulatory pathway for its Bigfoot Unity system as a part of the Bigfoot Unity Diabetes Management Program.